Agenus Inc. (AGEN) – A Snapshot of Recent Trading Activity
On Friday, the 23rd of October 2026, Agenus Inc. (ticker AGEN) experienced a modest uptick of 1.72 % during a 24‑hour trading window that concluded at 07:11 AM Central Europe time. At the close of this period, the stock was valued at USD 6.51 on the Nasdaq, a figure that sits comfortably above the 200‑day simple moving average of USD 4.85.
The company currently has 45.2 million shares outstanding, giving it a market capitalisation of USD 288.1 million. In the preceding day, trading volume reached USD 3.6 million, reflecting a relatively modest liquidity profile when compared with the broader sector.
Over the course of the last month, Agenus’ shares have declined 22.5 %, a downturn that underscores the volatility inherent in the biopharmaceutical market. Yet, the company’s long‑term performance remains robust: the 52‑week high of USD 10.31 was logged on September 30, 2026, while the 52‑week low of USD 2.71 occurred on February 5, 2026. These historical pivots suggest that the current price of USD 6.51 sits near the mid‑range of its recent trading envelope.
Peer Performance in the Same 24‑Hour Window
Agenus’ contemporaries in the biotech space exhibited a spectrum of outcomes in the same 24‑hour window:
| Stock | Ticker | % Change | Current Price (USD) | Market Capitalisation (USD) |
|---|---|---|---|---|
| Eightco | ORBS | +1.01 % | 0.79 | 344.9 million |
| Relmada Therapeutics | RLMD | +2.49 % | 3.29 | 342.4 million |
| Fidelity D&D | FDBC | +6.78 % | 62.97 | 342.5 million |
| Nautilus Biotechnology | NAUT | +6.27 % | 2.60 | 344.9 million |
| Opus Genetics | IRD | –7.28 % | 3.82 | 342.4 million |
While Fidelity D&D and Nautilus Biotechnology posted double‑digit gains, Opus Genetics suffered a sharp decline, highlighting the sector’s inherent risk‑reward dynamics. Agenus’ modest rise positions it within the upper tier of performers, suggesting that its recent market activity remains comparatively positive.
Company Overview
Agenus Inc. is a specialty biopharmaceutical firm headquartered in Lexington, United States, with a focused mandate on immuno‑oncology. Leveraging checkpoint antibodies and complementary agents, the company aims to deliver curative outcomes for patients across the globe. The firm’s public listing on the Nasdaq was inaugurated on February 4, 2000, and its growth trajectory has been driven by a portfolio of oncology‑centric therapeutics. For additional information regarding their product pipeline and corporate initiatives, the company’s website can be accessed at www.agenusbio.com .
This article provides a factual overview of Agenus Inc.’s recent trading performance, contextualised within its broader sector and historical price movements.
